OncoCyte Stock Price, News & Analysis (NYSEAMERICAN:OCX)

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte Corp (NYSEAMERICAN:OCX) announced its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). View OncoCyte's Earnings History.

OncoCyte is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for OncoCyte.

5 equities research analysts have issued twelve-month price targets for OncoCyte's stock. Their forecasts range from $6.00 to $8.00. On average, they expect OncoCyte's share price to reach $7.00 in the next year. This suggests a possible upside of 215.3% from the stock's current price. View Analyst Price Targets for OncoCyte.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.

Media stories about OCX stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OncoCyte earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for OncoCyte.

OncoCyte saw a drop in short interest during the month of August. As of August 15th, there was short interest totalling 1,007,700 shares, a drop of 18.8% from the July 15th total of 1,240,400 shares. Based on an average trading volume of 365,900 shares, the days-to-cover ratio is presently 2.8 days. Approximately 3.3% of the company's stock are short sold. View OncoCyte's Current Options Chain.

Some companies that are related to OncoCyte include Biotest (BIO), Theratechnologies (TH), Starpharma (SPL), Paradigm Biopharmaceuticals (PAR), Oxford BioMedica (OXB), Bellus Health (BLU), ProMetic Life Sciences (PLI), Rafael (RFL), CEL-SCI (CVM), Pfenex (PFNX), 22nd Century Group (XXII), Emblem (EMC), Emerald Health Therapeutics (EMH), Monash IVF Group (MVF) and Senesco Technologies (ELOX).

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include BioTime (BTX), Alnylam Pharmaceuticals (ALNY), Novocure (NVCR), Alibaba Group (BABA), Geron (GERN), Asterias Biotherapeutics (AST), Anavex Life Sciences (AVXL), Progenics Pharmaceuticals (PGNX), Apricus Biosciences (APRI) and AVEO Pharmaceuticals (AVEO).

OncoCyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.58%), BlackRock Inc. (2.99%), Vanguard Group Inc. (2.72%), Maven Securities LTD (0.41%), Bank of New York Mellon Corp (0.15%) and Northern Trust Corp (0.14%). Company insiders that own OncoCyte stock include Andrew Arno, Biotime Inc, Broadwood Partners, LP and Mitchell S Levine. View Institutional Ownership Trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust and Morgan Stanley. View Insider Buying and Selling for OncoCyte.

OCX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Maven Securities LTD, Vanguard Group Inc., Jane Street Group LLC, Bank of New York Mellon Corp, Doheny Asset Management CA, Charles Schwab Investment Management Inc. and Wells Fargo & Company MN. Company insiders that have bought OncoCyte stock in the last two years include Andrew Arno, Broadwood Partners, LP and Mitchell S Levine. View Insider Buying and Selling for OncoCyte.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OCX stock can currently be purchased for approximately $2.22.

OncoCyte has a market capitalization of $115.38 million. OncoCyte employs 12 workers across the globe.View Additional Information About OncoCyte.

The official website for OncoCyte is http://www.oncocyte.com/.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.